Administration of Elranatamab In the Real-World: Treatment Patterns, Healthcare Resource Utilization, Costs, Effectiveness, anD SafEty (ALTITUDE-2)

Study identification

• EU PAS number:
  EUPAS1000000293
• Study ID:
  1000000293
• Official title and acronym:
  Administration of Elranatamab In the Real-World: Treatment Patterns, Healthcare Resource Utilization, Costs, Effectiveness, anD SafEty (ALTITUDE-2)
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  This study aims to describe the real-world usage of elranatamab for the treatment of RRMM. To meet these objectives, the Clarify team will partner with Pfizer to create a curated dataset of Medicare FFS beneficiaries to serve as the foundation upon which to generate descriptive insights about this population.
• Study status:
  Planned

Research institutions and networks

Institutions

Pfizer

Clarify Health

Study timelines

Date when funding contract was signed

Planned: 15/05/2024

Study start date

Planned: 01/10/2024

Date of interim report, if expected

Planned: 18/12/2024

Date of final study report

Planned: 25/06/2025

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Pfizer

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable